Pfizer wins FDA approval for hemophilia B drug that will be first once-weekly treatment
The new drug would allow patients to produce the needed clotting protein for an extended period, reducing the need for ...
Medscape21h
FDA Approves Pfizer's Hympavzi for Hemophilia A, B
The monoclonal antibody is the first non-factor, once-weekly treatment approved in the United States for hemophilia B.
FDA approves first once-weekly drug treatment regimen for hemophilia
Patients suffering from hemophilia received a "meaningful" advancement on Friday when federal regulators approved the first ...
FiercePharma22h
Pfizer doubles down with its 2nd FDA hemophilia approval in 6 months
Six months after scoring FDA approval for hemophilia B gene therapy Beqvez, Pf | For the second time in six months, the FDA ...
Daily15h
FDA Approves New new treatment option for cutting bleeding in Hemophilia A or B
Hemophilia A and hemophilia B are genetic bleeding disorders caused by a dysfunction or deficiency of coagulation factor VIII ...
hemophilianewstoday22h
FDA approves marstacimab, now Hympavzi, for hemophilia
The FDA has approved Pfizer’s marstacimab under the brand name Hympavzi for adults and children with hemophilia A or B, ...
US FDA approves Pfizer's drug for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's once-a-week injection for the two main types of a rare bleeding ...
The American Journal of Managed Care23h
FDA Approves Marstacimab, First Weekly Sub-Q Option for Hemophilia B
The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...
Medpage Today on MSN20h
Marstacimab Gets FDA Nod for Hemophilia A or B Without Inhibitors
The FDA approved marstacimab (Hympavzi) for routine prophylaxis to prevent or reduce bleeding episodes in adults and ...
Managed Healthcare Executive20h
FDA Approves Hympavzi for Hemophilia A and B
The FDA approved Pfizer’s Hympavzi (marstacimab-hncq) to prevent or reduce the frequency of bleeding episodes in patients age ...
FDA Approves Pfizer's HYMPAVZI For Hemophilia A And B Treatment In Adults And Adolescents
Pfizer Inc. (PFE) announced Friday that the U.S. Food and Drug Administration has approved HYMPAVZI (marstacimab-hncq) for routine ...
U.S. FDA Approves Pfizer’s HYMPAVZI™ (marstacimab-hncq) for the Treatment of Adults and Adolescents with Hemophilia A or B Without Inhibitors
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved HYMPAVZI™ ...